Finished Western Medicine Doxycycline Hyclate Capsules 100mg GMP

Name: Finished Western Medicine Doxycycline Hyclate Capsules 100mg GMP
Brand: Shijiazhuang G-House Trading Co., Ltd.
SKU: 1987269531

Hebei, ChinaShijiazhuang G-House Trading Co., Ltd.

US$0.01

10,000 boxes

Product specifications

Packaging

Sample price:US$0.10/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

For oral administration

Model NO.

100mg

Suitable for

Elderly, Adult

State

Solid

Shape

Capsules

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Standard

Bp/USP

Delivery Time

30~60 Days

Group

Human

Storage Instructions

Dry Place

Transport Package

Carton

Specification

10 tablets/blister, 10 blisters/box(10×10)

Trademark

Customer brand

Origin

China

HS Code

3003209000

Production Capacity

5000000 Boxes/Year

Company profile

Importers and ExportersHigh Repeat Buyers ChoiceYears of Export ExperienceFast Delivery

Shijiazhuang G-House Trading Co., Ltd.

Hebei, China

Business Type: Manufacturer/Factory, Trading CompanyExport Year: 2008-08-13Nearest Port: Xingang, Qingdao, ShanghaiAverage Response Time: ≤5.95hTerms of Payment: LC, T/T, D/P, etc.International Commercial Terms(Incoterms): FOB, CFR, CIF

AI-Powered supplier vetting

SummaryShijiazhuang G-House Trading Co., Ltd. is a Chinese limited trading company primarily engaged in pharmaceuticals. Despite strong export activity and considerable customization capability, the company lacks certain service capabilities and comprehensive after-sales procedures. The firm provides OEM and ODM services but doesn't have a significant R&D focus or SDK availability. Financial data is available for the past three years, but overseas presence is limited.

Supplier typeThe supplier is identified as a limited company with a trading and manufacturing role, focusing on pharmaceuticals.

CertificationsThe supplier was audited by BV, but the result of the evaluation wasn't favorable, as indicated by the audit result '0'.

After-Sales capabilityThere are no written procedures or records for handling corrective actions or customer complaints, indicating a lack of systematic after-sales service capability.

Financial creditFinancial data is recorded for the past three years (2020, 2021, 2022), which suggests a level of financial transparency.

R&D capabilityThe supplier lacks innovation indicators like R&D with SDK availability and hasn't developed new products in the past year.

Production capacityThe supplier offers OEM and ODM services, indicating strong production capabilities in terms of design and manufacturing.

Customization capabilityThere is significant customization capability, with services ranging from minor to full customization.

Client casesThe supplier lacks overseas showrooms, agents, or branches and hasn't participated in offline trade shows, suggesting limited customer engagement globally.